TitleAssociate Professor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov; 15(11):1791-1799. PMID: 28579181; PMCID: PMC5901750.
      Citations: 33     Fields:    Translation:Humans
    2. Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA, National Comprehensive Cancer Network. Occult primary, version 3.2014. J Natl Compr Canc Netw. 2014 Jul; 12(7):969-74. PMID: 24994917.
      Citations: 11     Fields:    Translation:Humans
    3. Carlson H, Lenzi R, Raber MN, Varadhachary GR. A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary. Int J Clin Oncol. 2013 Apr; 18(2):226-31. PMID: 22218909.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    4. Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WK, National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines Occult primary. J Natl Compr Canc Netw. 2011 Dec; 9(12):1358-95. PMID: 22157556.
      Citations: 15     Fields:    Translation:Humans
    5. McHenry M, Parker PA, Baile WF, Lenzi R. Voice analysis during bad news discussion in oncology: reduced pitch, decreased speaking rate, and nonverbal communication of empathy. Support Care Cancer. 2012 May; 20(5):1073-8. PMID: 21573770.
      Citations: 6     Fields:    Translation:Humans
    6. Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res. 2011 Jun 15; 17(12):4063-70. PMID: 21531815.
      Citations: 41     Fields:    Translation:Humans
    7. Lenzi R, Baile WF, Costantini A, Grassi L, Parker PA. Communication training in oncology: results of intensive communication workshops for Italian oncologists. Eur J Cancer Care (Engl). 2011 Mar; 20(2):196-203. PMID: 20477861.
      Citations: 15     Fields:    Translation:Humans
    8. Costantini A, Baile WF, Lenzi R, Costantini M, Ziparo V, Marchetti P, Grassi L. Overcoming cultural barriers to giving bad news: feasibility of training to promote truth-telling to cancer patients. J Cancer Educ. 2009; 24(3):180-5. PMID: 19526404.
      Citations: 10     Fields:    Translation:Humans
    9. Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W. Occult primary. J Natl Compr Canc Netw. 2008 Nov; 6(10):1026-60. PMID: 19176200.
      Citations:    Fields:    Translation:Humans
    10. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008 Sep 20; 26(27):4442-8. PMID: 18802157.
      Citations: 74     Fields:    Translation:Humans
    11. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3496-502. PMID: 18640930.
      Citations: 250     Fields:    Translation:HumansCTClinical Trials
    12. Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, Rosenblum M, Freedman RS. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med. 2007 Dec 12; 5:66. PMID: 18076766; PMCID: PMC2248163.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    13. Hassan MM, Bondy ML, Wolff RA, Abbruzzese JL, Vauthey JN, Pisters PW, Evans DB, Khan R, Chou TH, Lenzi R, Jiao L, Li D. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol. 2007 Dec; 102(12):2696-707. PMID: 17764494; PMCID: PMC2423805.
      Citations: 126     Fields:    Translation:Humans
    14. Hassan MM, Abbruzzese JL, Bondy ML, Wolff RA, Vauthey JN, Pisters PW, Evans DB, Khan R, Lenzi R, Jiao L, Li D. Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. Cancer. 2007 Jun 15; 109(12):2547-56. PMID: 17492688; PMCID: PMC2215306.
      Citations: 17     Fields:    Translation:HumansPHPublic Health
    15. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. Metastatic patterns in adenocarcinoma. Cancer. 2006 Apr 01; 106(7):1624-33. PMID: 16518827.
      Citations: 307     Fields:    Translation:Humans
    16. Li D, Jiao L, Li Y, Doll MA, Hein DW, Bondy ML, Evans DB, Wolff RA, Lenzi R, Pisters PW, Abbruzzese JL, Hassan MM. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis. 2006 Jan; 27(1):103-11. PMID: 15987714; PMCID: PMC1350610.
      Citations: 41     Fields:    Translation:Humans
    17. Li D, Ahmed M, Li Y, Jiao L, Chou TH, Wolff RA, Lenzi R, Evans DB, Bondy ML, Pisters PW, Abbruzzese JL, Hassan MM. 5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1470-6. PMID: 15941958.
      Citations: 12     Fields:    Translation:Humans
    18. Ettinger DS, Arnoletti JP, Gockerman JP, Handorf C, Havlin KA, Jacobs CD, Javle M, Kvols L, Lenzi R, Rashid A, Rhoades CA, Ridge JA, Saltz L, Shulman LN, Sondak VK, Thompson JA, Twardowski P, Zhen W, National Comprehensive Cancer Network. Occult primary cancer clinical practice guidelines. J Natl Compr Canc Netw. 2005 Mar; 3(2):214-33. PMID: 19817031.
      Citations: 2     Fields:    Translation:Humans
    19. Xiong HQ, Plunkett W, Wolff R, Du M, Lenzi R, Abbruzzese JL. A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2005 Jun; 55(6):559-64. PMID: 15726370.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    20. Lenzi R, Baile WF, Berek J, Back A, Buckman R, Cohen L, Parker PA. Design, conduct and evaluation of a communication course for oncology fellows. J Cancer Educ. 2005; 20(3):143-9. PMID: 16122361.
      Citations: 10     Fields:    Translation:Humans
    21. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer. 2004 Aug 01; 101(3):466-75. PMID: 15274059.
      Citations: 106     Fields:    Translation:Humans
    22. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004 Jun 01; 100(11):2292-9. PMID: 15160331.
      Citations: 206     Fields:    Translation:HumansCTClinical Trials
    23. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004 May 01; 100(9):1776-85. PMID: 15112256.
      Citations: 59     Fields:    Translation:Humans
    24. Weinberg JS, Suki D, Hanbali F, Cohen ZR, Lenzi R, Sawaya R. Metastasis of esophageal carcinoma to the brain. Cancer. 2003 Nov 01; 98(9):1925-33. PMID: 14584076.
      Citations: 55     Fields:    Translation:Humans
    25. Cohen L, Baile WF, Henninger E, Agarwal SK, Kudelka AP, Lenzi R, Sterner J, Marshall GD. Physiological and psychological effects of delivering medical news using a simulated physician-patient scenario. J Behav Med. 2003 Oct; 26(5):459-71. PMID: 14593853.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    26. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003 Sep 15; 21(18):3402-8. PMID: 12885837.
      Citations: 133     Fields:    Translation:HumansCTClinical Trials
    27. Melichar B, Lenzi R, Rosenblum M, Kudelka AP, Kavanagh JJ, Melicharova K, Templin S, Garcia ME, Abbruzzese JL, Freedman RS. Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12. J Immunother. 2003 May-Jun; 26(3):270-6. PMID: 12806280.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    28. Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with M?llerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res. 2002 Dec; 8(12):3686-95. PMID: 12473577.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    29. Pentz RD, Lenzi R, Holmes F, Khan MM, Verschraegen C. Discussion of the do-not-resuscitate order: a pilot study of perceptions of patients with refractory cancer. Support Care Cancer. 2002 Nov; 10(8):573-8. PMID: 12436216.
      Citations: 12     Fields:    Translation:Humans
    30. Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, Lenzi R, Vauthey JN, Lee JE, Abbruzzese JL, Evans DB. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 2002 May 15; 20(10):2537-44. PMID: 12011133.
      Citations: 39     Fields:    Translation:Humans
    31. Baile WF, Lenzi R, Parker PA, Buckman R, Cohen L. Oncologists' attitudes toward and practices in giving bad news: an exploratory study. J Clin Oncol. 2002 Apr 15; 20(8):2189-96. PMID: 11956281.
      Citations: 104     Fields:    Translation:Humans
    32. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 2002 Apr 01; 52(5):1293-302. PMID: 11955742.
      Citations: 48     Fields:    Translation:Humans
    33. Lenzi R, Yalcin S, Evans DB, Abbruzzese JL. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest. 2002; 20(4):464-72. PMID: 12094541.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    34. Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res. 2001 Aug; 7(8):2246-53. PMID: 11489798.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    35. Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Lahoti S, Vauthey JN, Janjan NA. Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol. 2001 Jun; 28(3 Suppl 10):25-33. PMID: 11510031.
      Citations: 17     Fields:    Translation:Humans
    36. Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN, Lynch P, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM, Allen P, Brown T, Skibber J. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol. 2001 Apr; 24(2):107-12. PMID: 11319280.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    37. Parker PA, Baile WF, de Moor C, Lenzi R, Kudelka AP, Cohen L. Breaking bad news about cancer: patients' preferences for communication. J Clin Oncol. 2001 Apr 01; 19(7):2049-56. PMID: 11283138.
      Citations: 87     Fields:    Translation:Humans
    38. Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong A, Phan T, Nguyen Q, Abbruzzese JL. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol. 2001; 29(1):9-18. PMID: 11560155.
      Citations: 17     Fields:    Translation:Humans
    39. Crane CH, Janjan NA, Abbruzzese JL, Curley S, Vauthey J, Sawaf HB, Dubrow R, Allen P, Ellis LM, Hoff P, Wolff RA, Lenzi R, Brown TD, Lynch P, Cleary K, Rich TA, Skibber J. Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys. 2001 Jan 01; 49(1):107-16. PMID: 11163503.
      Citations: 15     Fields:    Translation:Humans
    40. Crane CH, Antolak JA, Rosen II, Forster KM, Evans DB, Janjan NA, Charnsangavej C, Pisters PW, Lenzi R, Papagikos MA, Wolff RA. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer. 2001; 30(3):123-32. PMID: 12540024.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    41. Janjan NA, Breslin T, Lenzi R, Rich TA, Skibber J. Avoidance of colostomy placement in advanced colorectal cancer with twice weekly hypofractionated radiation plus continuous infusion 5-fluorouracil. J Pain Symptom Manage. 2000 Oct; 20(4):266-72. PMID: 11027908.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    42. Janjan NA, Crane CN, Feig BW, Cleary K, Dubrow R, Curley SA, Ellis LM, Vauthey J, Lenzi R, Lynch P, Wolff R, Brown T, Pazdur R, Abbruzzese J, Hoff PM, Allen P, Brown B, Skibber J. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2000 Jun 01; 47(3):713-8. PMID: 10837955.
      Citations: 21     Fields:    Translation:Humans
    43. Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, Abbruzzese JL, Evans DB. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol. 2000 Feb; 18(4):860-7. PMID: 10673529.
      Citations: 17     Fields:    Translation:Humans
    44. Wolff RA, Chiao P, Lenzi R, Pisters PW, Lee JE, Janjan NA, Crane CH, Evans DB, Abbruzzese JL. Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs. 2000 Feb; 18(1):43-56. PMID: 10830140.
      Citations: 10     Fields:    Translation:HumansAnimals
    45. Melichar B, Nash MA, Lenzi R, Platsoucas CD, Freedman RS. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol. 2000 Jan; 119(1):19-27. PMID: 10606960; PMCID: PMC1905534.
      Citations: 11     Fields:    Translation:HumansCells
    46. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999 Nov; 5(11):3403-10. PMID: 10589751.
      Citations: 53     Fields:    Translation:Humans
    47. Baile WF, Kudelka AP, Beale EA, Glober GA, Myers EG, Greisinger AJ, Bast RC, Goldstein MG, Novack D, Lenzi R. Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness. Cancer. 1999 Sep 01; 86(5):887-97. PMID: 10463990.
      Citations: 66     Fields:    Translation:Humans
    48. Baile WF, Glober GA, Lenzi R, Beale EA, Kudelka AP. Discussing disease progression and end-of-life decisions. Oncology (Williston Park). 1999 Jul; 13(7):1021-31; discussion 1031-6, 1038. PMID: 10442349.
      Citations: 13     Fields:    Translation:Humans
    49. Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, Rich TA, Raijman I, Wolff RA, Lenzi R, Lee JE, Evans DB. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 1998 Dec; 16(12):3843-50. PMID: 9850029.
      Citations: 46     Fields:    Translation:Humans
    50. Nash MA, Lenzi R, Platsoucas CD, Freedman RS. RT-PCR quantitation of cytokine responses in vivo from specimens containing small numbers of cells during bioimmunotherapy. J Immunol Methods. 1998 Oct 01; 219(1-2):169-79. PMID: 9831398.
      Citations: 1     Fields:    Translation:Humans
    51. Kudelka AP, Lenzi R, Atkinson EN, Levy LB, Freedman RS. Is ascitic fluid interleukin-12 an independent prognostic factor in ovarian cancer? The necessity of correction milligram P values for multiple comparisons. J Clin Oncol. 1998 Sep; 16(9):3208-9. PMID: 9738599.
      Citations:    Fields:    Translation:Humans
    52. Janjan NA, Payne R, Gillis T, Podoloff D, Libshitz HI, Lenzi R, Theriault R, Martin C, Yasko A. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manage. 1998 Sep; 16(3):171-8. PMID: 9769619.
      Citations: 17     Fields:    Translation:Humans
    53. Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol. 1998 Jun; 16(6):2105-12. PMID: 9626210.
      Citations: 20     Fields:    Translation:Humans
    54. Nash MA, Lenzi R, Edwards CL, Kavanagh JJ, Kudelka AP, Verschraegen CF, Platsoucas CD, Freedman RS. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines. Clin Exp Immunol. 1998 May; 112(2):172-80. PMID: 9649178; PMCID: PMC1904977.
      Citations: 9     Fields:    Translation:HumansCells
    55. Lenzi R, Kim EE, Raber MN, Abbruzzese JL. Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan. Ann Oncol. 1998 Feb; 9(2):213-6. PMID: 9553668.
      Citations: 4     Fields:    Translation:Humans
    56. Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Abbruzzese JL, Ordo?ez NG. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol. 1997 May; 15(5):2056-66. PMID: 9164218.
      Citations: 11     Fields:    Translation:Humans
    57. Baile WF, Lenzi R, Kudelka AP, Maguire P, Novack D, Goldstein M, Myers EG, Bast RC. Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. J Cancer Educ. 1997; 12(3):166-73. PMID: 9376255.
      Citations: 37     Fields:    
    58. Evans DB, Lee JE, Pisters PW, Charnsangavej C, Ellis LM, Chiao PJ, Lenzi R, Abbruzzese JL. Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. Cancer Treat Res. 1997; 90:109-25. PMID: 9367080.
      Citations: 6     Fields:    Translation:Humans
    59. Abbruzzese JL, Abbruzzese MC, Lenzi R, Raber MN, Hess KR. Are time or intensity factors important to the definition of metastases of unknown origin? J Natl Cancer Inst. 1996 Apr 03; 88(7):462-3. PMID: 8618241.
      Citations:    Fields:    Translation:Humans
    60. Eftekhari F, Wallace S, Silva EG, Lenzi R. Merkel cell carcinoma of the skin: imaging and clinical features in 93 cases. Br J Radiol. 1996 Mar; 69(819):226-33. PMID: 8800866.
      Citations: 18     Fields:    Translation:Humans
    61. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995 Aug; 13(8):2094-103. PMID: 7636553.
      Citations: 71     Fields:    Translation:Humans
    62. Cagnoni PJ, Lenzi R, Wisch N, Seremetis S, Rand JH. Spurious fibrinogen levels secondary to pyroglobulinemia in Waldenstr?m's macroglobulinemia. Am J Hematol. 1995 Feb; 48(2):126-7. PMID: 7847327.
      Citations:    Fields:    Translation:HumansCells
    63. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994 Jun; 12(6):1272-80. PMID: 8201389.
      Citations: 69     Fields:    Translation:Humans
    64. Lenzi R, Frost P, Abbruzzese JL. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines. Anticancer Res. 1994 Jan-Feb; 14(1A):247-51. PMID: 7513143.
      Citations: 3     Fields:    Translation:HumansCells
    65. Tarsetti F, Lenzi R, Salvi R, Schuler E, Rijhsinghani K, Lenzen R, Tavoloni N. Liver carcinogenesis associated with feeding of ethionine in a choline-free diet: evidence against a role of oval cells in the emergence of hepatocellular carcinoma. Hepatology. 1993 Sep; 18(3):596-603. PMID: 8359801.
      Citations: 8     Fields:    Translation:Animals
    66. Abbruzzese JL, Lenzi R, Raber MN, Pathak S, Frost P. The biology of unknown primary tumors. Semin Oncol. 1993 Jun; 20(3):238-43. PMID: 8503019.
      Citations: 13     Fields:    Translation:HumansCells
    67. Lenzi R, Raber MN, Frost P, Schmidt S, Abbruzzese JL. Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. Eur J Cancer. 1993; 29A(11):1634. PMID: 8217373.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    68. Lenzi R, Fossella FV, Lee JS. Systemic treatment of non-small-cell lung cancer. Compr Ther. 1992 Mar; 18(3):27-30. PMID: 1315236.
      Citations:    Fields:    Translation:Humans
    69. Lenzi R, Liu MH, Tarsetti F, Slott PA, Alpini G, Zhai WR, Paronetto F, Lenzen R, Tavoloni N. Histogenesis of bile duct-like cells proliferating during ethionine hepatocarcinogenesis. Evidence for a biliary epithelial nature of oval cells. Lab Invest. 1992 Mar; 66(3):390-402. PMID: 1538592.
      Citations: 19     Fields:    Translation:Animals
    70. Lenzi R, Liu MH, Lenzen R, Han T, Alpini G, Tavoloni N. Distribution of glucose-6-phosphatase activity in normal, hyperplastic, and preneoplastic rat liver. Virchows Arch B Cell Pathol Incl Mol Pathol. 1991; 61(4):279-87. PMID: 1685820.
      Citations: 2     Fields:    Translation:Animals
    71. Lenzi R, Alpini G, Liu MH, Rand JH, Tavoloni N. von Willebrand factor antigen is not an accurate marker of rat and guinea pig liver endothelial cells. Liver. 1990 Dec; 10(6):372-9. PMID: 2074734.
      Citations: 4     Fields:    Translation:Animals
    72. Alpini G, Lenzi R, Zhai WR, Liu MH, Slott PA, Paronetto F, Tavoloni N. Isolation of a nonparenchymal liver cell fraction enriched in cells with biliary epithelial phenotypes. Gastroenterology. 1989 Nov; 97(5):1248-60. PMID: 2477298.
      Citations: 12     Fields:    Translation:AnimalsCells
    73. Alpini G, Lenzi R, Zhai WR, Slott PA, Liu MH, Sarkozi L, Tavoloni N. Bile secretory function of intrahepatic biliary epithelium in the rat. Am J Physiol. 1989 Jul; 257(1 Pt 1):G124-33. PMID: 2750903.
      Citations: 30     Fields:    Translation:Animals
    74. Alpini G, Lenzi R, Sarkozi L, Tavoloni N. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J Clin Invest. 1988 Feb; 81(2):569-78. PMID: 2448343; PMCID: PMC329605.
      Citations: 110     Fields:    Translation:Animals
    75. Lenzi R, Rand JH, Spiera H. Anticardiolipin antibodies in pregnant patients with systemic lupus erythematosus. N Engl J Med. 1986 May 22; 314(21):1392-3. PMID: 3702950.
      Citations: 4     Fields:    Translation:Humans
    76. p53 Mutations are infrequent and do not correlate with the metastatic potential of human melanoma cells. International Journal of Oncology. 3:19-22.
    77. A pilot study of paclitaxel in previously treated patients with metastatic unknown primary carcinomas. Oncology Reports. 2:1127-1128.
    78. The Hainsworth/Greco article reviewed. Oncology. 14:576-579.
    79. Brain Metastasis from Upper Gastrointestinal Tract Cancers. 362-380.
    80. Phase II study of prolonged oral etoposide in refractory ovarian cancer. International Journal of Gynecological Cancer. 5:351-354.
    81. Carcinoma of Unknown Primary. 1792-1803.e2.
    82. Phase I and II trials of a laboratory-derived synergistic combination of cisplatin and 2'-deoxy-5-azacytidine. International Journal of Oncology. 6:447-450.
    LENZI's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (354)
    Co-Authors (37)
    Similar People (60)
    Same Department Expand Description